[go: up one dir, main page]

PE20240050A1 - Inhibidores de cdk2 y metodos de uso de los mismos - Google Patents

Inhibidores de cdk2 y metodos de uso de los mismos

Info

Publication number
PE20240050A1
PE20240050A1 PE2023002221A PE2023002221A PE20240050A1 PE 20240050 A1 PE20240050 A1 PE 20240050A1 PE 2023002221 A PE2023002221 A PE 2023002221A PE 2023002221 A PE2023002221 A PE 2023002221A PE 20240050 A1 PE20240050 A1 PE 20240050A1
Authority
PE
Peru
Prior art keywords
carbonyl
oxobutan
diazaspiro
carboxamide
pyrazole
Prior art date
Application number
PE2023002221A
Other languages
English (en)
Inventor
Louise Clare Kirman
Carl Eric Schwartz
Wojtek Michowski
Jr Dale A Porter
Justin Ripper
John Feutrill
John Paul Sherrill
Thomas P Blaisdell
Original Assignee
Cedilla Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedilla Therapeutics Inc filed Critical Cedilla Therapeutics Inc
Publication of PE20240050A1 publication Critical patent/PE20240050A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS ESPIROCICLICOS DE FORMULA (I) DONDE L2, L3, R6, R8 Y RA SON TAL COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: (S)-N-((2S,3R)-3-(BENCILOXI)-1-(METILAMINO)-1-OXOBUTAN-2-IL)-2-(2-CICLOPROPILACETIL)-6-(1H-PIRAZOL-4-CARBONIL)-2,6-DIAZASPIRO[3.4]OCTANO-8-CARBOXAMIDA; N-((2S,3R)-3-(BENCILOXI)-1-(METILAMINO)-1-OXOBUTAN-2-IL)-2-(2,2-DIMETILCICLOPROPANO-1-CARBONIL)-6-(1-METIL-1H-PIRAZOL-4-CARBONIL)-2,6-DIAZASPIRO[3.4]OCTANO-8-CARBOXAMIDA; 6-(1-BENCIL-1H-PIRAZOL-4-CARBONIL)-2-(2,2-DIMETILCICLOPROPANO-1-CARBONIL)-N-((2S,3R)-3-METOXI-1-(METILAMINO)-1-OXOBUTAN-2-IL)-2,6-DIAZASPIRO[3.4]OCTANO-8-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA DEPENDIENTE DE CICLINA 2 (CDK2) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON LA MISMA.
PE2023002221A 2021-01-29 2022-01-28 Inhibidores de cdk2 y metodos de uso de los mismos PE20240050A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163143360P 2021-01-29 2021-01-29
PCT/US2022/070409 WO2022165513A1 (en) 2021-01-29 2022-01-28 Cdk2 inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
PE20240050A1 true PE20240050A1 (es) 2024-01-09

Family

ID=82654899

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002221A PE20240050A1 (es) 2021-01-29 2022-01-28 Inhibidores de cdk2 y metodos de uso de los mismos

Country Status (19)

Country Link
US (2) US12065445B2 (es)
EP (1) EP4284365A4 (es)
JP (1) JP2024505261A (es)
KR (1) KR20230142745A (es)
CN (1) CN117177744A (es)
AU (1) AU2022214618A1 (es)
BR (1) BR112023015210A2 (es)
CA (1) CA3208618A1 (es)
CL (1) CL2023002223A1 (es)
CO (1) CO2023010023A2 (es)
CR (1) CR20230362A (es)
DO (1) DOP2023000145A (es)
EC (1) ECSP23057264A (es)
IL (1) IL304728A (es)
MX (1) MX2023008968A (es)
PE (1) PE20240050A1 (es)
PH (1) PH12023552079A1 (es)
TW (1) TW202239402A (es)
WO (1) WO2022165513A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12023552079A1 (en) 2021-01-29 2024-01-22 Cedilla Therapeutics Inc Cdk2 inhibitors and methods of using the same
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
CA3225439A1 (en) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024026486A2 (en) * 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024026483A2 (en) * 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024026481A2 (en) * 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024026479A2 (en) * 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024102421A2 (en) * 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
SE0302811D0 (sv) 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10360745A1 (de) 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
EP1720545B1 (en) 2004-03-03 2014-10-29 ChemoCentryx, Inc. Bicyclic and bridged nitrogen heterocycles
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
WO2007056155A1 (en) 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
US20080247964A1 (en) 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2007140383A2 (en) 2006-05-30 2007-12-06 Neurogen Corporation Spirocyclic sulfonamides and related compounds
WO2008033456A1 (en) 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
EP2212318B1 (en) * 2007-10-29 2013-07-24 Merck Sharp & Dohme Corp. Thiazole derivatives as protein kinase inhibitors
US7935725B2 (en) 2007-10-31 2011-05-03 Janssen Pharmaceutica Nv Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
BRPI1010649A2 (pt) 2009-06-08 2016-06-07 Gruenenthal Gmbh benzimidazóis, benzotiazóis e benzoxazoles substituídos.
WO2011028596A1 (en) * 2009-09-04 2011-03-10 Glaxosmithkline Llc Chemical compounds
US8633183B2 (en) 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
KR101528688B1 (ko) 2010-12-02 2015-06-12 상하이 드 노보 파마테크 컴퍼니 리미티드 헤테로사이클릭 유도체, 이의 제조 방법 및 이의 의학적 용도
CN102952118B (zh) 2011-08-17 2016-03-23 上海迪诺医药科技有限公司 聚（adp-核糖）聚合酶抑制剂、制备方法及其用途
WO2013131010A2 (en) 2012-03-02 2013-09-06 Icahn School Of Medicine At Mount Sinai Function of chemokine receptor ccr8 in melanoma metastasis
KR20150023373A (ko) 2012-06-13 2015-03-05 에프. 호프만-라 로슈 아게 신규한 다이아자스피로사이클로알칸 및 아자스피로사이클로알칸
WO2015048567A1 (en) 2013-09-26 2015-04-02 Sanford-Burnham Medical Research Institute Spirocyclic ebi2 modulators
WO2015051230A1 (en) 2013-10-04 2015-04-09 Drexel University Novel compositions useful for inhibiting hiv-1 infection and methods using same
DK3126352T3 (en) 2014-04-04 2019-01-21 Syros Pharmaceuticals Inc CYCLINE INDEPENDENT KINASE 7 INHIBITORS (CDK7)
US9856264B2 (en) 2014-04-28 2018-01-02 Medshine Discovery Inc. Isoquinolinesulfonyl derivative as RHO kinase inhibitor
EP3143023B1 (en) 2014-05-15 2018-04-11 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases
JP6616786B2 (ja) 2014-05-19 2019-12-04 メリアル インコーポレイテッド 駆虫性化合物
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
CN105461693B (zh) 2014-09-26 2019-10-25 广东东阳光药业有限公司 Crth2拮抗剂化合物及其用途
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
PT3331864T (pt) 2015-08-04 2022-01-18 Chong Kun Dang Pharmaceutical Corp Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos
US10323038B2 (en) 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US11370790B2 (en) 2016-08-01 2022-06-28 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
KR102493364B1 (ko) 2016-09-14 2023-01-27 얀센 파마슈티카 엔.브이. Menin-mll 상호작용의 융합 바이사이클릭 억제제
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
CN117298275A (zh) 2017-03-24 2023-12-29 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
US10266497B2 (en) 2017-05-23 2019-04-23 Abide Therapeutics, Inc. Pyrazole MAGL inhibitors
TWI712615B (zh) 2017-07-21 2020-12-11 大陸商四川海思科製藥有限公司 肽醯胺類化合物、其製備方法及醫藥用途
KR20200046053A (ko) 2017-08-29 2020-05-06 룬드벡 라 졸라 리서치 센터 인코포레이티드 스피로사이클 화합물 및 이를 제조하고 사용하는 방법
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
CN111902386A (zh) 2017-12-28 2020-11-06 瑞璞鑫(苏州)生物科技有限公司 作为fto抑制剂的苯基甲酮衍生物
CN110156674A (zh) 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
WO2019169156A1 (en) * 2018-02-28 2019-09-06 The Trustees Of The University Of Pennsylvania Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
CA3117210A1 (en) 2018-10-24 2020-04-30 Araxes Pharma Llc 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis
ES2955037T3 (es) 2018-11-22 2023-11-28 Hoffmann La Roche Nuevos compuestos heterocíclicos
SG11202105320YA (en) 2018-11-28 2021-06-29 H Lundbeck As Methods of treating disease with magl inhibitors
EP3887373A1 (en) 2018-11-29 2021-10-06 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
CN111138358B (zh) 2019-12-17 2023-04-18 中国药科大学 Usp8抑制剂及其制备方法与应用
PH12023552079A1 (en) 2021-01-29 2024-01-22 Cedilla Therapeutics Inc Cdk2 inhibitors and methods of using the same
CA3225439A1 (en) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024026483A2 (en) 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024026486A2 (en) 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024026481A2 (en) 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024026484A2 (en) 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024026479A2 (en) 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same

Also Published As

Publication number Publication date
US20230109076A1 (en) 2023-04-06
EP4284365A4 (en) 2024-12-18
PH12023552079A1 (en) 2024-01-22
CR20230362A (es) 2023-11-23
WO2022165513A1 (en) 2022-08-04
KR20230142745A (ko) 2023-10-11
DOP2023000145A (es) 2023-10-31
EP4284365A1 (en) 2023-12-06
TW202239402A (zh) 2022-10-16
IL304728A (en) 2023-09-01
BR112023015210A2 (pt) 2023-11-07
ECSP23057264A (es) 2023-09-29
CO2023010023A2 (es) 2023-09-08
AU2022214618A1 (en) 2023-08-17
CA3208618A1 (en) 2022-08-04
CL2023002223A1 (es) 2023-12-29
US20240174680A1 (en) 2024-05-30
CN117177744A (zh) 2023-12-05
US12065445B2 (en) 2024-08-20
MX2023008968A (es) 2023-09-22
JP2024505261A (ja) 2024-02-05

Similar Documents

Publication Publication Date Title
PE20240050A1 (es) Inhibidores de cdk2 y metodos de uso de los mismos
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PE20221905A1 (es) Aminas biciclicas como inhibidoras de la cdk2
PE20090964A1 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b
CL2017003445A1 (es) Formas solidas y formulaciones de compuestos de imidazopirazina.
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
EA200701854A1 (ru) Соединения - ингибиторы дипептидилпептидазы-iv, способы их получения, а также фармацевтические композиции, содержащие указанные соединения в качестве активного ингредиента
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
UY29427A1 (es) Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones
CY1111197T1 (el) Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
MY144659A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
EA200500299A1 (ru) Пиразольные композиции, используемые в качестве ингибиторов gsk-3
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
UY31334A1 (es) 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
PE20212196A1 (es) Compuestos, composiciones, y metodos para modular la actividad cdk9
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
MX2022001743A (es) Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma.